Using RNA therapeutics to promote healthy aging.

Shuying Chen, Qian Chen, Xinru You, Zhuoming Zhou, Na Kong, Fabrisia Ambrosio, Yihai Cao, Reza Abdi, Wei Tao

Center for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.Center for Nanomedicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. · pubmed

Paper

Abstract

Aging is characterized by a gradual decline of cellular and physiological functions over time and an increased risk of different diseases. RNA therapeutics constitute an emerging approach to target the molecular mechanisms of aging and age-related diseases via rational design and have several advantages over traditional drug therapies, including high specificity, low toxicity and the potential for rapid development and production. Here, we discuss the latest developments in RNA therapeutics designed to promote healthy aging, including RNA activation, messenger RNA therapy, RNA interference, antisense oligonucleotides, aptamers and CRISPR-Cas-mediated RNA editing. We also review the latest preclinical and clinical studies of RNA technology for treating age-related diseases, including neurodegenerative, cardiovascular and musculoskeletal diseases. Finally, we discuss the challenges of RNA technology aimed at supporting healthy aging. We anticipate that the fusion of RNA therapeutics and aging biology will have an important effect on the development of new medicines and maximization of their efficacy.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

RNA therapeutics can target the molecular mechanisms of aging to promote healthy aging. The paper discusses innovative approaches to address the root causes of aging and age-related diseases, aligning with longevity research goals.

Author of this paper? Send a correction.